GenMark Dx Plans Respiratory Viral, CYP450 Panels as Q2 Revenues Rise 162 Percent | GenomeWeb

By Justin Petrone

GenMark Diagnostics this week reported revenue growth of 162 percent for its first quarter since going public in the US.

The company, which was based in London and known as Osmetech before going public in the US at the end of May, also announced that it is seeking a new CEO. Jon Faiz Kayyem, who previously served in that role, is now chief scientific officer. Christopher Gleeson, chairman of the firm, will serve as CEO on an interim basis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.